Global Prostate Cancer Nuclear Medicine Diagnostics Market Size, Status and Forecast 2019-2025

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Prostate Cancer Nuclear Medicine Diagnostics Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 SPECT
  • 1.4.3 PET
• 1.5 Market by Application
  • 1.5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Prostate Cancer Nuclear Medicine Diagnostics Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Prostate Cancer Nuclear Medicine Diagnostics Industry
    • 1.6.1.1 Prostate Cancer Nuclear Medicine Diagnostics Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Prostate Cancer Nuclear Medicine Diagnostics Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Prostate Cancer Nuclear Medicine Diagnostics Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Prostate Cancer Nuclear Medicine Diagnostics Market Perspective (2015-2026)
• 2.2 Prostate Cancer Nuclear Medicine Diagnostics Growth Trends by Regions
  • 2.2.1 Prostate Cancer Nuclear Medicine Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Prostate Cancer Nuclear Medicine Diagnostics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Prostate Cancer Nuclear Medicine Diagnostics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Prostate Cancer Nuclear Medicine Diagnostics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Market Size
  • 3.1.1 Global Top Prostate Cancer Nuclear Medicine Diagnostics Players by Revenue (2015-2020)
  • 3.1.2 Global Prostate Cancer Nuclear Medicine Diagnostics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio
  • 3.2.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Prostate Cancer Nuclear Medicine Diagnostics Revenue in 2019
• 3.3 Prostate Cancer Nuclear Medicine Diagnostics Key Players Head office and Area Served
• 3.4 Key Players Prostate Cancer Nuclear Medicine Diagnostics Product Solution and Service
• 3.5 Date of Enter into Prostate Cancer Nuclear Medicine Diagnostics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size by Type (2015-2020)
• 4.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Type (2021-2026)

5 Prostate Cancer Nuclear Medicine Diagnostics Breakdown Data by Application (2015-2026)

• 5.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2015-2020)
• 5.2 Global Prostate Cancer Nuclear Medicine Diagnostics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2015-2020)
• 6.2 Prostate Cancer Nuclear Medicine Diagnostics Key Players in North America (2019-2020)
• 6.3 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2015-2020)
• 6.4 North America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size (2015-2020)
• 7.2 Prostate Cancer Nuclear Medicine Diagnostics Key Players in Europe (2019-2020)
• 7.3 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2015-2020)
• 7.4 Europe Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2015-2020)

8 China

• 8.1 China Prostate Cancer Nuclear Medicine Diagnostics Market Size (2015-2020)
• 8.2 Prostate Cancer Nuclear Medicine Diagnostics Key Players in China (2019-2020)
• 8.3 China Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2015-2020)
• 8.4 China Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size (2015-2020)
• 9.2 Prostate Cancer Nuclear Medicine Diagnostics Key Players in Japan (2019-2020)
• 9.3 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2015-2020)
• 9.4 Japan Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size (2015-2020)
• 10.2 Prostate Cancer Nuclear Medicine Diagnostics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2015-2020)

11 India

• 11.1 India Prostate Cancer Nuclear Medicine Diagnostics Market Size (2015-2020)
• 11.2 Prostate Cancer Nuclear Medicine Diagnostics Key Players in India (2019-2020)
• 11.3 India Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2015-2020)
• 11.4 India Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Prostate Cancer Nuclear Medicine Diagnostics Market Size (2015-2020)
• 12.2 Prostate Cancer Nuclear Medicine Diagnostics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Type (2015-2020)
• 12.4 Central & South America Prostate Cancer Nuclear Medicine Diagnostics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Blue Earth Diagnostics
  • 13.1.1 Blue Earth Diagnostics Company Details
  • 13.1.2 Blue Earth Diagnostics Business Overview and Its Total Revenue
  • 13.1.3 Blue Earth Diagnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.1.4 Blue Earth Diagnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020))
  • 13.1.5 Blue Earth Diagnostics Recent Development
• 13.2 PETNET Solutions
  • 13.2.1 PETNET Solutions Company Details
  • 13.2.2 PETNET Solutions Business Overview and Its Total Revenue
  • 13.2.3 PETNET Solutions Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.2.4 PETNET Solutions Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.2.5 PETNET Solutions Recent Development
• 13.3 Cardinal Health
  • 13.3.1 Cardinal Health Company Details
  • 13.3.2 Cardinal Health Business Overview and Its Total Revenue
  • 13.3.3 Cardinal Health Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.3.4 Cardinal Health Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.3.5 Cardinal Health Recent Development
• 13.4 Lantheus Medical Imaging
  • 13.4.1 Lantheus Medical Imaging Company Details
  • 13.4.2 Lantheus Medical Imaging Business Overview and Its Total Revenue
  • 13.4.3 Lantheus Medical Imaging Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.4.4 Lantheus Medical Imaging Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.4.5 Lantheus Medical Imaging Recent Development
• 13.5 Jubilant Pharma
  • 13.5.1 Jubilant Pharma Company Details
  • 13.5.2 Jubilant Pharma Business Overview and Its Total Revenue
  • 13.5.3 Jubilant Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.5.4 Jubilant Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.5.5 Jubilant Pharma Recent Development
• 13.6 NCM-USA
  • 13.6.1 NCM-USA Company Details
  • 13.6.2 NCM-USA Business Overview and Its Total Revenue
  • 13.6.3 NCM-USA Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.6.4 NCM-USA Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.6.5 NCM-USA Recent Development
• 13.7 Progenics Pharma
  • 13.7.1 Progenics Pharma Company Details
  • 13.7.2 Progenics Pharma Business Overview and Its Total Revenue
  • 13.7.3 Progenics Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.7.4 Progenics Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.7.5 Progenics Pharma Recent Development
• 13.8 Telix Pharma
  • 13.8.1 Telix Pharma Company Details
  • 13.8.2 Telix Pharma Business Overview and Its Total Revenue
  • 13.8.3 Telix Pharma Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.8.4 Telix Pharma Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.8.5 Telix Pharma Recent Development
• 13.9 ImaginAb
  • 13.9.1 ImaginAb Company Details
  • 13.9.2 ImaginAb Business Overview and Its Total Revenue
  • 13.9.3 ImaginAb Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.9.4 ImaginAb Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.9.5 ImaginAb Recent Development
• 13.10 Theragnostics
  • 13.10.1 Theragnostics Company Details
  • 13.10.2 Theragnostics Business Overview and Its Total Revenue
  • 13.10.3 Theragnostics Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 13.10.4 Theragnostics Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 13.10.5 Theragnostics Recent Development
• 13.11 Novartis
  • 10.11.1 Novartis Company Details
  • 10.11.2 Novartis Business Overview and Its Total Revenue
  • 10.11.3 Novartis Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 10.11.4 Novartis Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 10.11.5 Novartis Recent Development
• 13.12 Alliance Medical
  • 10.12.1 Alliance Medical Company Details
  • 10.12.2 Alliance Medical Business Overview and Its Total Revenue
  • 10.12.3 Alliance Medical Prostate Cancer Nuclear Medicine Diagnostics Introduction
  • 10.12.4 Alliance Medical Revenue in Prostate Cancer Nuclear Medicine Diagnostics Business (2015-2020)
  • 10.12.5 Alliance Medical Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer